Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424119 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8934166 | 0.92 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL8933916 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8933879 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL8933882 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5071832 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL13776402 | 0.86 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL8933845 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL8933885 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL8933920 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | BOUNTRA CHARANJIT | 2006-05-04 | — | — | US | claimed |
| EP-1572237-A1 | COMBINATIONS OF VANILLOID ANTAGONIST AND NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056394-A1 | COMBINATIONS OF A VANILLOID ANTAGONIST AND AN NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| EP-1239879-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | claimed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| US-5547975-A | ANTIARTHRIC AGENTS, ANALGESICS AND ANTIPYRETICS; INHIBITORS OF CYCLOOXYGENASE II; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 1996-08-20 | — | — | US | claimed |
| WO-1996009304-A1 | BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | claimed |
| US-20250339458-A1 | USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-06 | — | — | US | disclosed |
| US-20240148889-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2023096904-A2 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2021252708-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210338709-A1 | USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-04 | — | — | US | disclosed |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| US-5565482-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | G.D. SEARLE & CO. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5547975-A | ANTIARTHRIC AGENTS, ANALGESICS AND ANTIPYRETICS; INHIBITORS OF CYCLOOXYGENASE II; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 1996-08-20 | — | — | US | disclosed |
| WO-1996009304-A1 | BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148889-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | ABCB4, PCSK7, F12 | PTGS2 4570/4885PTGS1 4271/4885 |
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | TRPV1, TRPV2, TRPV3 | PTGS2 129/4885PTGS1 59/4885 |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | ADORA1, ADORA2A, ADORA2B | PTGS2 25/4885PTGS1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.